Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.49 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.44 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.42 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.41 |
| ▸ | PKM | P14618 | 2/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | CA2 | P00918 | 6/20 | 0.40 |
| ▸ | CA12 | O43570 | 2/20 | 0.40 |
| ▸ | CA1 | P00915 | 2/20 | 0.40 |
| ▸ | CA9 | Q16790 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29948804 | 1.00 | TRPV4 (0.49) | TRPV4KEAP1NFE2L2L3MBTL1OPRD1 | |
| SCHEMBL2804046 | 0.87 | L3MBTL1 (0.45) | TRPV4L3MBTL1OPRD1PKMCA2 | |
| SCHEMBL31235134 | 0.82 | CA2 (0.51) | KEAP1NFE2L2L3MBTL1PKMCA2 | |
| SCHEMBL16936936 | 0.82 | CA2 (0.51) | KEAP1NFE2L2L3MBTL1PKMCA2 | |
| SCHEMBL29482639 | 0.81 | TRPV4 (0.68) | TRPV4L3MBTL1GAACA2CA12 | |
| SCHEMBL1817972 | 0.81 | TRPV4 (0.53) | TRPV4L3MBTL1PKMSMN1; SMN2CA2 | |
| SCHEMBL1817970 | 0.81 | PKM (0.55) | TRPV4L3MBTL1PKMSMN1; SMN2 | |
| SCHEMBL74997 | 0.81 | TRPV4 (0.68) | TRPV4L3MBTL1GAACA2CA12 | |
| SCHEMBL27724224 | 0.81 | KEAP1 (0.47) | KEAP1NFE2L2L3MBTL1OPRD1PKM | |
| SCHEMBL1817484 | 0.79 | TRPV4 (0.47) | TRPV4L3MBTL1PKMSMN1; SMN2GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119118894-A | TRPV4 receptor ligands | 犹他大学研究基金会 | 2024-12-13 | — | — | CN | disclosed |
| WO-2024243025-A1 | NAPHTHYL-SUBSTITUTED PYRIDO[4,3-D]PYRIMIDINES AND RELATED COMPOUNDS AND THEIR USE IN TREATING MEDICAL CONDITIONS | Ikena Oncology, Inc. (US) | 2024-11-28 | — | — | WO | disclosed |
| US-20230026696-A1 | TRPV4 RECEPTOR LIGANDS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2023-01-26 | — | — | US | disclosed |
| CN-115052478-A | TRPV4 receptor ligands | 犹他大学研究基金会 | 2022-09-13 | — | — | CN | disclosed |
| WO-2021102314-A1 | TRPV4 RECEPTOR LIGANDS | UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) | 2021-05-27 | — | — | WO | disclosed |
| CN-110114358-A | Novel compound and pharmacologically acceptable salt thereof | 明治制果药业株式会社 | 2019-08-09 | — | — | CN | disclosed |
| CN-109311894-A | N- (substituted-phenyl) -sulfonamide derivatives as kinase inhibitors | 内尔维阿诺医学科学有限公司 | 2019-02-05 | — | — | CN | disclosed |
| EP-2964635-B1 | ANTIVIRAL COMPOUNDS | HOFFMANN LA ROCHE (CH) | 2018-05-02 | — | — | EP | disclosed |
| CN-104168958-B | Diaryl sulfonamides useful for the treatment of inflammation and cancer | 坎塞拉有限公司 | 2017-12-01 | — | — | CN | disclosed |
| CN-107257788-A | Benzenesulfonamide derivatives as inverse agonists of the retinoid-related orphan receptor gamma (ROR gamma (t)) | 盖尔德马研究及发展公司 | 2017-10-17 | — | — | CN | disclosed |
| WO-2006010629-A1 | PIPERAZINE DERIVATIVES USEFUL FOR THE TREATMENT OF GASTROINTESTINAL DISORDERS | GLAXO GROUP LIMITED (GB) | 2006-02-02 | — | — | WO | disclosed |
| US-6673824-B1 | HYPOTENSIVE AGENTS | BRISTOL-MYERS SQUIBB CO. | 2004-01-06 | — | — | US | disclosed |
| US-6107320-A | Phenyl sulfonamide endothelin antagonists | BRISTOL-MYERS SQUIBB CO. (US) | 2000-08-22 | — | — | US | disclosed |
| EP-0516257-B1 | Phenylbenzo[b]furans and -thiophenes, procedures for their preparation, and pharmaceutical compositions containing the same | SCHERING AG (DE) | 1998-08-05 | — | — | EP | disclosed |
| EP-0569193-B1 | N-isoxazole-phenylsulfonamide derivatives and their use as endothelin antagonists | SQUIBB & SONS INC (US) | 1997-02-26 | — | — | EP | disclosed |
| US-5514696-A | Phenyl sulfonamide endothelin antagonists | BRISTOL-MYERS SQUIBB CO. (US) | 1996-05-07 | — | — | US | disclosed |
| US-5470854-A | Antiestrogens | SCHERING AKTIENGESELLSCHAFT (DE) | 1995-11-28 | — | — | US | disclosed |
| EP-0569193-A1 | N-isoxazole-phenylsulfonamide derivatives and their use as endothelin antagonists | E.R. SQUIBB & SONS, INC. (US) | 1993-11-10 | — | — | EP | disclosed |
| WO-1992021669-A1 | 2-PHENYLBENZO[B]FURANS AND THIOPHENES, METHODS OF PREPARING THEM AND PHARMACEUTICAL PREPARATIONS CONTAINING THEM | SCHERING AKTIENGESELLSCHAFT (DE) | 1992-12-10 | — | — | WO | disclosed |
| EP-0516257-A1 | Phenylbenzo[b]furans and -thiophenes, procedures for their preparation, and pharmaceutical compositions containing the same | SCHERING AKTIENGESELLSCHAFT (DE) | 1992-12-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230026696-A1 | TRPV4 RECEPTOR LIGANDS | TRPV4, TRPV2, TRPV3 | TRPV4 1/4885KEAP1 1338/4885NFE2L2 1731/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.